Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study
Authors
Keywords
Epidemiology, Bisphosphonate, Female breast cancer, Ovarian cancer, Cervical cancer
Journal
Archives of Osteoporosis
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-17
DOI
10.1007/s11657-019-0588-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies
- (2017) Ying-Ju Ou et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer
- (2015) Polly A. Newcomb et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study
- (2015) Ju-Young Shin et al. BMJ-British Medical Journal
- Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study
- (2015) Ju-Young Shin et al. BMJ-British Medical Journal
- Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial
- (2014) Sharon Hensley Alford et al. CANCER
- The effect of bisphosphonates on the risk of endometrial and ovarian malignancies
- (2014) Gad Rennert et al. GYNECOLOGIC ONCOLOGY
- Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer
- (2014) Trisha F. Hue et al. JAMA Internal Medicine
- Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case–control studies using two primary-care databases
- (2013) Y Vinogradova et al. BRITISH JOURNAL OF CANCER
- A Higher Dosage of Oral Alendronate Will Increase the Subsequent Cancer Risk of Osteoporosis Patients in Taiwan: A Population-Based Cohort Study
- (2013) Wen-Yuan Lee et al. PLoS One
- Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study
- (2012) Chia-Hung Chiang et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Use of Bisphosphonates and Risk of Breast Cancer
- (2011) Peter Vestergaard et al. CALCIFIED TISSUE INTERNATIONAL
- Exposure to oral bisphosphonates and risk of cancer
- (2011) Chris R. Cardwell et al. INTERNATIONAL JOURNAL OF CANCER
- Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer
- (2011) G. M. Monsees et al. JNCI-Journal of the National Cancer Institute
- Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class
- (2010) Philippe Clézardin BONE
- Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
- (2010) P A Newcomb et al. BRITISH JOURNAL OF CANCER
- Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women
- (2010) Rowan T. Chlebowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer
- (2010) Gad Rennert et al. JOURNAL OF CLINICAL ONCOLOGY
- Bisphosphonates for the treatment of osteoporosis: insights for clinicians
- (2010) E. Michael Lewiecki Therapeutic Advances in Chronic Disease
- Bisphosphonates: Mechanism of Action and Role in Clinical Practice
- (2009) Matthew T. Drake et al. MAYO CLINIC PROCEEDINGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More